Chelerythrine inhibits the progress of esophageal squamous cell carcinoma  via PINK1-Parkin-mediated mitophagy.
CHE activated PINK1-Prakin-mediated mitophagy and disrupted mitochondrial homeostasis leading to cell death, thus providing evidence for the selection of anti-ESCC drugs.